Ferring Pharmaceuticals Announces Changes to Board of Directors
1.7.2021 08:30:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals announced today that Frederik Paulsen is stepping down from his role as Chairman of the Board of Directors* and transitioning to the role of Honorary Chairman. Lars Rebien Sørensen is appointed Chairman of the Board of Directors. Jean-Frédéric Paulsen is also appointed to the Board of Directors. All of these changes are effective immediately.
Mr. Paulsen has been Chairman of Ferring’s Board of Directors since 1988. During Mr Paulsen’s tenure, the company has delivered impressive growth and expanded rapidly into new markets, with a presence in almost 60 countries and revenues of nearly EUR 2 billion today.
“My father Frederik Paulsen and stepmother Eva Paulsen founded Ferring in 1950, and it has been an honour to continue their legacy of pioneering science while driving the global expansion of the company,” said Mr Paulsen. “As Ferring enters its next phase of growth, this is the right moment for me to hand over the reins. With his extraordinary track record, I am confident that Lars will effectively guide Ferring towards its ambitious long-term strategic and financial targets, while keeping alive the pioneering spirit on which the company was built.”
Lars Rebien Sørensen has over three decades of general management experience in the pharmaceutical industry and was President and CEO of Novo Nordisk A/S from 2000 until 2016, spearheading the company’s growth into a highly respected and successful global pharmaceutical company. Today, Mr Sørensen is Chair of the Board of the Novo Nordisk Foundation, Chair of the Board of Novo Holdings A/S, a board member of Thermo Fischer Scientific Inc., as well as Chair of the Advisory Board of Axcel Management A/S.
“I’m excited to take on the role of Chairman of the Board of Directors at Ferring Pharmaceuticals and will seek to build on the company’s strong foundations and continue its impressive track record of growth,” said Mr Sørensen. “I look forward to working with the Board of Directors and the Executive Committee, to bring the company’s long-term strategy to life and help more people around the world build families and live better lives.”
Jean-Frédéric Paulsen is Chairman of Ferring Ventures S.A, in addition to other activities. He previously served as Senior Advisor to four Ministers of Economy and Sustainable Development of Georgia and has worked at Mars Inc, Coca-Cola and Credit Suisse.
After he steps down as Chairman, Frederik Paulsen will transition to Honorary Chairman of Ferring’s Board of Directors, continuing to provide support and ensuring a smooth transition for the Board. Mr Paulsen will also dedicate more time to his passions of polar exploration and climate change science, in addition to his diverse philanthropic activities and the oversight of his other investments.
*Refers to the Board of Directors of Ferring Holding S.A - the parent company of the Ferring Pharmaceuticals group
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
# # #
Ferring International Center SA
Ch. de la Vergognausaz, 50
CH-1162 Saint-Prex
Switzerland
www.ferring.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005972/en/
Contact information
For more information
Bhavin Vaid
Head of Corporate Communications
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
Lindsey Rodger
Senior Manager, Corporate Communications
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
